{
    "clinical_study": {
        "@rank": "77232", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "eculizumab", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the efficacy and safety of eculizumab\n      treatment as compared to placebo in relapsing NMO patients using a time to first relapse\n      study design."
        }, 
        "brief_title": "A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuromyelitis Optica", 
            "Neuromyelitis Optica Spectrum Disorder"
        ], 
        "condition_browse": {
            "mesh_term": "Neuromyelitis Optica"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Male or female patients \u2265 18 years old\n\n          2. Diagnosis of NMO or NMO spectrum disorder\n\n          3. All patients must be NMO-IgG seropositive\n\n          4. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last\n             24 months (with at least 1 relapse in the 12 months prior to the Screening)\n\n          5. EDSS score \u22647\n\n          6. Immunosuppressive therapy is allowed provided patients have been on a stable\n             maintenance dose prior to the Screening and remain on a stable dose for the duration\n             of the study\n\n        Key Exclusion Criteria:\n\n          1. Use of rituximab within 3 months prior to screening\n\n          2. Use of mitoxantrone within 3 months prior to screening\n\n          3. Use of IVIg within 3 weeks prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892345", 
            "org_study_id": "ECU-NMO-301"
        }, 
        "intervention": {
            "arm_group_label": "eculizumab", 
            "description": "Eculizumab IV Infusion", 
            "intervention_name": "Eculizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Neuromyelitis Optica", 
            "Neuromyelitis Optica Spectrum Disorder", 
            "Devic's disease, Transverse Myelitis", 
            "Optic Neuritis", 
            "relapse", 
            "eculizumab", 
            "soliris", 
            "NMO-IgG", 
            "CNS Autoimmune Disorders", 
            "Demyelinating Disorders"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }, 
                    "name": "The Research Center of Southern California"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "John Hopkins University School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10466"
                    }, 
                    "name": "Montefiore Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Swedish Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)", 
        "overall_contact": {
            "email": "clinicaltrials@alxn.com", 
            "last_name": "Alexion Pharmaceuticals (Sponsor)"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "On-trial NMO Relapse, as defined by the protocol.", 
            "measure": "Time to first relapse", 
            "safety_issue": "No", 
            "time_frame": "from baseline to end of study"
        }, 
        "reference": {
            "PMID": "23623397", 
            "citation": "Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892345"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events, vital signs and laboratory assessments", 
            "measure": "Overall safety and tolerability of eculizumab", 
            "safety_issue": "Yes", 
            "time_frame": "from baseline to end of study"
        }, 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}